Cat. No.: HY-N0246

Saikosaponin A

5 Cited Publications

Customer Review

Based on 5 publication(s) in Google Scholar

Saikosaponin A is the main active ingredient in Bupleurum chinense, which can regulate lipid metabolism and promote cholesterol efflux in early atherosclerosis. In addition, Saikosaponin A may also serve as a potential peroxisome proliferator-activated receptor γ (PPAR-γ) agonist, significantly promoting the expression of PPAR-γ. Saikosaponin A can be used in the study of hyperlipidemic pancreatitis.

For research use only. We do not sell to patients.

Purity: 99.31%
CAS No.: 20736-09-8
Formula: C₄₂H₆₈O₁₃
Molecular Weight:780.98

Storage:

-20°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Saikosaponin A Chemical Structure

CAS No.: 20736-09-8

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (5)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

Cellular Effect

Cell Line	Type	Value	Description	References
A-375	IC₅₀	23.9 μM Compound: 1	Cytotoxicity against human A375 cells after 48 hrs by SRB assay Cytotoxicity against human A375 cells after 48 hrs by SRB assay	[PMID: 19467877]
A549	IC₅₀	14.54 μM Compound: 8	Cytotoxicity against human A549 cells assessed as induction of cell death incubated for 2 days by MTT assay Cytotoxicity against human A549 cells assessed as induction of cell death incubated for 2 days by MTT assay	[PMID: 26259802]
A549	IC₅₀	17.7 μM Compound: 1	Cytotoxicity against human A549 cells after 48 hrs by SRB assay Cytotoxicity against human A549 cells after 48 hrs by SRB assay	[PMID: 19467877]
ACHN	IC₅₀	>50 μM Compound: 1	Cytotoxicity against human ACHN cells after 48 hrs by SRB assay Cytotoxicity against human ACHN cells after 48 hrs by SRB assay	[PMID: 19467877]
Bcap37	IC₅₀	13.96 μM Compound: 8	Cytotoxicity against human Bcap37 cells assessed as induction of cell death incubated for 2 days by MTT assay Cytotoxicity against human Bcap37 cells assessed as induction of cell death incubated for 2 days by MTT assay	[PMID: 26259802]
C32	IC₅₀	43.5 μM Compound: 1	Cytotoxicity against human C32 cells after 48 hrs by SRB assay Cytotoxicity against human C32 cells after 48 hrs by SRB assay	[PMID: 19467877]
Caco-2	IC₅₀	17.9 μM Compound: 1	Cytotoxicity against human Caco-2 cells after 48 hrs by SRB assay Cytotoxicity against human Caco-2 cells after 48 hrs by SRB assay	[PMID: 19467877]
COR-L23	IC₅₀	0.6 μM Compound: 1	Cytotoxicity against human COR-L23 cells after 48 hrs by SRB assay Cytotoxicity against human COR-L23 cells after 48 hrs by SRB assay	[PMID: 19467877]
Hep 3B2	IC₅₀	13.01 μM Compound: 8	Cytotoxicity against human Hep3B cells assessed as induction of cell death incubated for 2 days by MTT assay Cytotoxicity against human Hep3B cells assessed as induction of cell death incubated for 2 days by MTT assay	[PMID: 26259802]
HepG2	IC₅₀	8.34 μM Compound: 8	Cytotoxicity against human HepG2 cells assessed as induction of cell death incubated for 2 days by MTT assay Cytotoxicity against human HepG2 cells assessed as induction of cell death incubated for 2 days by MTT assay	[PMID: 26259802]
LNCaP	IC₅₀	>50 μM Compound: 1	Cytotoxicity against human LNCAP cells after 48 hrs by SRB assay Cytotoxicity against human LNCAP cells after 48 hrs by SRB assay	[PMID: 19467877]
MCF7	IC₅₀	>50 μM Compound: 1	Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay	[PMID: 19467877]
MCF7	IC₅₀	18.99 μM Compound: 8	Cytotoxicity against human MCF7 cells assessed as induction of cell death incubated for 2 days by MTT assay Cytotoxicity against human MCF7 cells assessed as induction of cell death incubated for 2 days by MTT assay	[PMID: 26259802]
RAW264.7	IC₅₀	>200 μM Compound: 1	Cytotoxicity against mouse RAW264.7 cells by MTT assay Cytotoxicity against mouse RAW264.7 cells by MTT assay	[PMID: 19467877]
RAW264.7	IC₅₀	101.8 μM Compound: 1	Antiinflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as inhibition of NO production after 24 hrs by Griess reagent method Antiinflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as inhibition of NO production after 24 hrs by Griess reagent method	[PMID: 19467877]

In Vitro

Saikosaponin A (5-15 μM, 24 h) did not affect the viability of human osteoarthritis chondrocytes^[1].
Saikosaponin A (5-15 μM, 24 h) inhibits IL-1β (HY-P73149)-induced NO and PGE2 production and NF-κB activation^[1].
Saikosaponin A (5-15 μM, 24 h) up-regulates the expression of LXRα in a dose-dependent manner^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis

Cell Line:

Human osteoarthritis chondrocytes
Concentration:

5, 10, 15 μM
Incubation Time:

24 h
Result:

Inhibited the levels of phosphorylation of NF-κB p65 and IκBα induced by IL-1β.
Up-regulated the expression of LXRα in a dose-dependent manner.

In Vivo

Saikosaponin A (1-10 mg/kg, i.p, 7 d) attenuates the morphological changes in the small intestine induced by 5-FU^[2].
Saikosaponin-A (1-10 mg/kg, i.p, 7 d) enhances the decrease of antioxidant enzymes in intestinal tissue caused by 5-FU^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

5-FU (HY-90006)-induced mucositis in BALB/c mice modle^[2]
Dosage:

1, 5, 10 mg/kg/day, 7 d
Administration:

injected intraperitoneally (i.p)
Result:

Reduced villus blunting, crypt cells apoptosis, and inflammatory cell infiltration.
Decreased concentration of GSH, GST, Catalase, and SOD in intestinal tissue.

Chemical Information

CAS No. 20736-09-8
Appearance Solid
Molecular Weight 780.98
Formula C₄₂H₆₈O₁₃
Color White to off-white
SMILES

OC[C@H]1O[C@](O[C@@H]2[C@@H](O)[C@@](O[C@@H]3[C@@](C)(CO)[C@@](CC[C@]4(C)[C@]5([H])C=C[C@@]6(OC7)[C@@]4(C)C[C@H](O)[C@]87[C@@]6([H])CC(C)(C)CC8)([H])[C@]5(C)CC3)([H])O[C@H](C)[C@@H]2O)([H])[C@H](O)[C@@H](O)[C@@H]1O
Structure Classification
- Terpenoids
- Triterpenes
Initial Source
- Plants
- Umbelliferae
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

-20°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (5)

All RT-PCRWBHistological Imaging/StainingIPIF

Sort by:

Journal Impact Factor

Mol Med Rep

Saikosaponin A protects against uremic toxin indole‑3 acetic acid‑induced damage to the myocardium. [Abstract]

2023 Sep;28(3):159. PMID: 37417356

Saikosaponin A purchased from MedChemExpress. Usage Cited in: Mol Med Rep. 2023 Sep;28(3):159. [Abstract]

Cardiomyocytes were pretreated with Saikosaponin A (SSA) (1, 10 and 30 µmol/L) for 1 h then exposed to IAA (50 µmol/L) for 48 h and mRNA expression levels of ANP, BNP and β-MHC were analyzed by qPCR.

Saikosaponin A purchased from MedChemExpress. Usage Cited in: Mol Med Rep. 2023 Sep;28(3):159. [Abstract]

Cardiomyocytes were pretreated with Saikosaponin A (SSA) (30 µmol/L) for 1 h and then exposed to IAA (50 µmol/L) for 48 h and Trim16 protein expression measured by Western blotting.

Saikosaponin A purchased from MedChemExpress. Usage Cited in: Mol Med Rep. 2023 Sep;28(3):159. [Abstract]

Representative micrographs (magnification, 10×) of hematoxylin and eosin-stained transverse sections from hearts of control, IAA- and IAA + Saikosaponin A (SSA) (40 mg/kg, i.g.)-treated mice.

Saikosaponin A purchased from MedChemExpress. Usage Cited in: Mol Med Rep. 2023 Sep;28(3):159. [Abstract]

Cardiomyocytes were transfected with siTrim16 or scrambled siRNA (siCntl), treated with Saikosaponin A (SSA) (30 µmol/L) for 1 h, then incubated with IAA (50 µmol/L) for 48 h. K48 ubiquitination of RIP2 was measured by immunoprecipitation.

Saikosaponin A purchased from MedChemExpress. Usage Cited in: Mol Med Rep. 2023 Sep;28(3):159. [Abstract]

Cell size was observed by immunofluorescence using a troponin antibody treated with Saikosaponin A (SSA) (30 µmol/L).
Pestic Biochem Physiol

Mechanistic insights into chlorogenic acid and caffeic acid as novel juvenile hormone antagonists. [Abstract]

2025 Dec:215:106655. PMID: 41162045
Front Cell Neurosci

Neuroprotective effects of saikosaponin-A in ethanol-induced glia-mediated neuroinflammation, oxidative stress via RAGE/TLR4/NFkB signaling. [Abstract]

2025 Aug 18:19:1625362. PMID: 40901367
Nutr Neurosci

Protective effect and mechanism of Saikosaponin A against oxidative damage in cochlear hair cells in vitro. [Abstract]

2025 Sep 29:1-12. PMID: 41017590
Biochem Biophys Res Commun

Engineered MAP30ER: A plant toxin-derived platform for EGFR-Targeted delivery of protein and chemotherapeutic payloads. [Abstract]

2025 Jun 10:776:152184. PMID: 40517671

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (128.04 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.2804 mL

6.4022 mL

12.8044 mL

5 mM

0.2561 mL

1.2804 mL

2.5609 mL

10 mM

0.1280 mL

0.6402 mL

1.2804 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (3.20 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (3.20 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (3.20 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline

Solubility: 10 mg/mL (12.80 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (282 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Gao H, et al. Saikosaponin A inhibits IL-1β-induced inflammatory mediators in human osteoarthritis chondrocytes by activating LXRα. Oncotarget. 2017 Sep 30;8(51):88941-88950. [Content Brief]

[2]. Jawad Ali, et al. Mucoprotective effects of Saikosaponin-A in 5-fluorouracil-induced intestinal mucositis in mice model. Life Sci. 2019. [Content Brief]

[3]. Feng P, et al. Saikosaponin a attenuates hyperlipidemic pancreatitis in rats via the PPAR‑γ/NF‑κB signaling pathway[J]. Experimental and therapeutic medicine, 2020, 19(2): 1203-1212. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.2804 mL	6.4022 mL	12.8044 mL	32.0111 mL
	5 mM	0.2561 mL	1.2804 mL	2.5609 mL	6.4022 mL
	10 mM	0.1280 mL	0.6402 mL	1.2804 mL	3.2011 mL
	15 mM	0.0854 mL	0.4268 mL	0.8536 mL	2.1341 mL
	20 mM	0.0640 mL	0.3201 mL	0.6402 mL	1.6006 mL
	25 mM	0.0512 mL	0.2561 mL	0.5122 mL	1.2804 mL
	30 mM	0.0427 mL	0.2134 mL	0.4268 mL	1.0670 mL
	40 mM	0.0320 mL	0.1601 mL	0.3201 mL	0.8003 mL
	50 mM	0.0256 mL	0.1280 mL	0.2561 mL	0.6402 mL
	60 mM	0.0213 mL	0.1067 mL	0.2134 mL	0.5335 mL
	80 mM	0.0160 mL	0.0800 mL	0.1601 mL	0.4001 mL
	100 mM	0.0128 mL	0.0640 mL	0.1280 mL	0.3201 mL

Keywords

Saikosaponin A

5 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Saikosaponin A

Anti-Infection Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

Natural Product Library

Glycoside Compound Library

Anti-Cardiovascular Disease Compound Library

Antibacterial Compound Library

Terpenoids Library

Pyroptosis Compound Library

Traditional Chinese Medicine Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Lipid Metabolism Compound Library

Targeted Diversity Library

Anti-Cancer Natural Product Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Nuclear Receptor Compound Library

Heterocyclic Compound Library

Metabolic Enzyme Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Tibetan Medicine Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Natural Product Diversity Scaffold Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Saikosaponin A

Biological Activity

Chemical Information

Publications (5)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Saikosaponin A Related Classifications

HY-N0246 Related Classifications